AMGEN INC
AMGN evidence brief
What we can confirm
- BioSniper Score:
- 6.2 / 10
- Market Cap:
- $206.25B
- Lead Asset:
- aimovig (Approved)
What it means
What to watch
Prepared research question
What matters most for AMGN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AMGN
Amgen Inc. (AMGN) is a large-cap biopharmaceutical company with a diversified portfolio spanning approved therapies, biosimilars, and a late-stage pipeline including obesity and immunology candidates.
Key risk: Biosimilar pressure on older franchises
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 10 pipeline candidates · 137 clinical trials · 2 catalysts · 11 FDA decisions for AMGEN INC.
Amgen Inc. (AMGN) is a large-cap biopharmaceutical company with a diversified portfolio spanning approved therapies, biosimilars, and a late-stage pipeline including obesity and immunology candidates.
- Cash & equivalents of $13,989.0M as of 2026-06-30 [sec].
- Total revenue of $10,054.0M and net income of $2,375.0M as of 2026-06-30 [sec].
- Shareholders' equity of $11,688.0M as of 2026-06-30 [sec].
- Experimental drug dazodalibep met the main goal of a late-stage trial for Sjögren’s disease, showing statistically significant and clinically meaningful improvements [news · 2026-09-27].
- Biosimilars business is driving growth, helping offset patent losses in key branded drugs [news · 2026-06-23].
What works
- Strong cash position of $13,989.0M as of 2026-06-30 provides financial flexibility for R&D and operations [sec].
- Late-stage pipeline progress, including dazodalibep's success in Sjögren’s disease trial, supports future growth [news · 2026-09-27].
- Biosimilars business is a growth driver, offsetting patent losses on older branded drugs [news · 2026-06-23].
- Broad product growth is funding a deeper late-stage pipeline push [news · 2026-08-05].
What to weigh
- Biosimilar pressure on older franchises remains a structural challenge [news · 2026-08-05].
- Patent losses on key branded drugs require offsetting growth from biosimilars and pipeline [news · 2026-06-23].
- Dependence on late-stage pipeline success for future revenue growth introduces execution risk [news · 2026-09-27].
From the filings
Quoted directly from source documents.
Dazodalibep met main goal in Sjögren’s disease trial
“Amgen’s dazodalibep produced a statistically significant and clinically meaningful improvement on a standard score of how the disease affects organs and systems.”
News · September 22, 2026
Biosimilars driving growth
“AMGN's biosimilars business is driving growth, with new launches and a deep pipeline helping offset patent losses in key branded drugs.”
News · June 23, 2026
Catalyst timeline
- 2026-10-12 · Phase1_Start: Phase1_Start: A Phase 1, Open-label, Randomized, Parallel Group Study to Assess the Relative Bioavailability of Two Maridebart Cafraglutide (AMG 133) Drug Products in Participants Living With Overweight or Obesity — This study will assess bioavailability of two formulations of the obesity drug candidate AMG 133.
- 2026-10-31 · Phase2_Start: Phase2_Start: Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age With Immunoglobulin G4-related Disease (IgG4-RD) — This trial evaluates inebilizumab in pediatric IgG4-RD patients, expanding the drug's potential indication.
- 2028-06-30 · Phase3_Start: Phase3_Start: A Phase 3, Open-label, Randomized, Controlled Trial of Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukaemia — This trial compares subcutaneous vs intravenous administration of blinatumomab in adult ALL patients.
Risks & what to watch (3)›
Key risks
- Biosimilar pressure on older franchises — Biosimilar competition continues to pressure older branded drug revenues [news · 2026-08-05].
- Patent losses on key drugs — Patent expirations on key branded drugs require offsetting growth from biosimilars and pipeline [news · 2026-06-23].
- Pipeline execution risk — Future revenue growth depends on successful late-stage pipeline development [news · 2026-09-27].
What to watch
- Phase 1 start of maridebart cafraglutide (AMG 133) bioavailability study on 2026-10-12 [catalyst].
- Phase 2 start of inebilizumab in children with IgG4-RD on 2026-10-31 [catalyst].
- Phase 3 start of subcutaneous vs intravenous blinatumomab in ALL on 2028-06-30 [catalyst].
- Continued biosimilar launches and their impact on revenue growth [news · 2026-06-23].
Sources: Catalysts · News · Pipeline · Generated October 12, 2026 · How we verify sources →
Run AMGEN INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AMGEN INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 7.18 · 1% dilution
Lead: Approved
10 candidates
2 upcoming, next in ~17d
0 buys · 7 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of Apr 24, 2026- % of float
- 2.6%
- Days to cover
- 5.4
- Shares short
- 13,981,275
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AMGN short interestGovernance
Frequently asked questions
What is the AI investment thesis for AMGEN INC?
Amgen Inc. (AMGN) is a large-cap biopharmaceutical company with a diversified portfolio spanning approved therapies, biosimilars, and a late-stage pipeline including obesity and immunology candidates.
What is AMGEN INC's lead drug candidate?
AMGEN INC's most advanced tracked candidate is aimovig (Approved).
What is AMGEN INC's next catalyst?
AMGEN INC's next tracked catalyst is a Phase2_Start event — "Phase2_Start: Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age With Immunoglobulin G4-related Disease (IgG4-RD)" — expected October 31, 2026.
Who is the CEO of AMGEN INC?
Mr. Robert A. Bradway is the chief executive officer of AMGEN INC (AMGN).
Where is AMGEN INC headquartered?
AMGEN INC (AMGN) is headquartered in Thousand Oaks, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.